Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data

INTRODUCTION: Few studies have compared adherence between long-acting injectable antipsychotics, especially for newer agents like aripiprazole once-monthly 400 mg (AOM 400; aripiprazole monohydrate) and oral antipsychotics, in patients with schizophrenia or bipolar I disorder (BD-I) in a real-world...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Tingjian, Greene, Mallik, Chang, Eunice, Hartry, Ann, Touya, Maëlys, Broder, Michael S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182631/
https://www.ncbi.nlm.nih.gov/pubmed/30206822
http://dx.doi.org/10.1007/s12325-018-0785-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182631/
https://www.ncbi.nlm.nih.gov/pubmed/30206822
http://dx.doi.org/10.1007/s12325-018-0785-y

Ejemplares similares